Boston Scientific announces scheduled presentations at Heart Rhythm Society 2015

Boston Scientific today announced that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in Boston on May 13-16.

Medtronic to unveil first-of-its-kind clinical data for cardiac therapies at Heart Rhythm 2015

Medtronic plc today announced its schedule of notable clinical studies that will be presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston, including two late-breaking clinical trials featuring the Evera MRI® SureScan® implantable cardioverter-defibrillator (ICD) System and Micra® Transcatheter Pacing System (TPS).

Thumbnail

Get ready for SCAI, HRS

This is the month for subspecialty cardiology conferences in the U.S., with two major meetings setting anchors on each coast.

Thumbnail

CEO & HRS Leader’s Strategy: Listen, Ask, Recruit & Step Back

As an early career electrophysiologist, Richard I. Fogel, MD, learned to raise his hand when projects needed a captain. Now he’s CEO of the St. Vincent Medical Group in Indianapolis and president of the Heart Rhythm Society (HRS). His formula? Listen, ask good questions, surround yourself with talented people and let them do their jobs, he explains in a Q&A with Cardiovascular Business.

Silk Road Medical announces 30 day results in the Roadster clinical trial for carotid artery revascularization

Sunnyvale, CA. -- Silk Road Medical, Inc. announced the 30 day outcomes from the ROADSTER IDE Study at the VIVA 2014 Vascular Interventional Advances Annual Conference in Las Vegas, Nevada. The trial studied the treatment of carotid artery stenosis with a new device and hybrid procedure combining the best elements of carotid endarterectomy (CEA) and carotid artery stenting (CAS).

Thumbnail

VIVA.14: Promising 1-year results for drug-coated balloons in diabetics

Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

VIVA.14: Zilver PTX holds strong at five years

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

Thumbnail

VIVA.14: DISRUPT PAD brings lithoplasty technique to peripheral lesions

Shockwaves appear to have early success in breaking up calcified lesions safely. In research presented Nov. 5 at the 2014 Vascular Interventional Advances (VIVA) meeting in Las Vegas, a lithotripsy-with-balloon technique used on peripheral artery lesions resulted in all patients achieving less than 50 percent stenosis. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup